文献速递心境障碍

莫沙必利促进TREK1-HTR4复合体内化并发挥快速抗抑郁样作用

Mosapride promotes internalization of a TREK1-HTR4 complex and exerts rapid antidepressant-like effects.
PubMed 文献 · Mol Psychiatry · 2026-08-01

该研究建立BiLC细胞筛选平台,在体外及海马组织中鉴定出TREK1与5-羟色胺受体4(HTR4)形成复合物。HTR4激动剂莫沙必利诱导膜上TREK1-HTR4复合体内化、以HTR4依赖方式降低TREK1通道活性;小鼠口服莫沙必利5天改善LPS诱导的抑郁样行为并保留海马神经发生标志物,而破坏该复合物可减弱上述效应。

要点

  • 莫沙必利经HTR4诱导TREK1-HTR4复合体内化并抑制TREK1通道活性。
  • 小鼠口服莫沙必利5天改善LPS诱导抑郁样行为并保留海马神经发生标志物。
  • 竞争性破坏TREK1-HTR4复合物可减弱莫沙必利的神经发生与行为效应。

核心结论

  • HTR4动态调控TREK1的转运与功能,靶向GPCR调控TREK1可能成为抑郁障碍治疗策略。

研究设计与样本

  • 研究建立基于生物分子发光互补(BiLC)的细胞筛选平台监测激动剂引起的膜相关TREK1变化。
  • 在体外及天然海马组织中使用生物分子荧光互补(BiFC)、免疫共沉淀(Co-IP)和邻位连接 assay(PLA)鉴定TREK1-HTR4复合物。
  • 采用活细胞成像与电生理记录评估莫沙必利对TREK1-HTR4复合物分布及TREK1通道活性的影响。
  • 体内对小鼠口服莫沙必利5天,评估LPS诱导抑郁样行为及海马神经发生标志物。
  • 通过病毒表达TREK1 C端相互作用结构域(C1)竞争性破坏TREK1-HTR4复合物以检验因果作用。

主要发现

  • 在体外及天然海马组织中鉴定出TREK1与HTR4形成复合物。
  • 莫沙必利处理诱导质膜相关TREK1-HTR4复合物向细胞内再分布/内化。
  • 电生理记录显示莫沙必利以HTR4依赖方式降低TREK1通道活性。
  • 小鼠口服莫沙必利5天改善LPS诱导的抑郁样行为并保留海马神经发生相关标志物。
  • 病毒表达TREK1 C端相互作用结构域(C1)减弱莫沙必利的神经发生与行为效应。

关键数值与推荐

  • 莫沙必利为HTR4激动剂,可诱导TREK1-HTR4复合体内化。
  • 小鼠口服莫沙必利持续5天。
  • 莫沙必利以HTR4依赖方式降低TREK1通道活性。
  • 病毒表达TREK1 C端相互作用结构域(C1)可竞争性破坏TREK1-HTR4复合物。

临床怎么用

  • 提示HTR4激动剂莫沙必利可能通过调控TREK1转运与活性发挥抗抑郁样作用。
  • 支持将GPCR调控TREK1作为抑郁障碍潜在治疗方向进行进一步研究。
  • 动物实验中需注意莫沙必利效应依赖TREK1-HTR4复合物完整性。

局限性

  • 原文摘要未报告临床人群数据,结果主要来自细胞与小鼠实验。
  • 原文摘要未报告莫沙必利在人体中的疗效与安全性数据。
  • 原文摘要未报告样本量、效应量及统计阈值等定量信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) remains a critical global health burden, and a substantial proportion of patients exhibit insufficient responses to conventional monoaminergic antidepressants. Selective inhibition of the two-pore domain potassium channel TREK1 has emerged as a promising antidepressant strategy; however, the regulatory mechanisms controlling TREK1 trafficking-particularly its functional coupling with G protein-coupled receptors (GPCRs)-remain poorly understood. Here, we established a cell-based screening platform using a biomolecular luminescence complementation (BiLC) assay to monitor agonist-induced changes in membrane-associated TREK1. Using this platform, we identified a TREK1-5-hydroxytryptamine receptor 4 (HTR4) complex in vitro and in native hippocampal tissues using biomolecular fluorescence complementation (BiFC), co-immunoprecipitation (Co-IP), and proximity ligation assays (PLA). Live-cell imaging demonstrated that treatment with the HTR4 agonist mosapride induces redistribution/internalization of a plasma membrane-associated TREK1-HTR4 pool into intracellular compartments. Electrophysiological recordings further confirmed that mosapride reduces TREK1 channel activity in an HTR4-dependent manner. In vivo, oral administration of mosapride for five days ameliorated lipopolysaccharide (LPS)-induced depressive-like behaviors in mice and preserved markers associated with hippocampal neurogenesis. Notably, viral expression of the TREK1 C-terminal interaction domain (C1), which competitively disrupts the TREK1-HTR4 complex, attenuated the neurogenic and behavioral effects of mosapride, supporting a causal role of TREK1 regulation in mediating these antidepressant-like actions. Collectively, our findings reveal a previously unrecognized mechanism in which HTR4 dynamically regulates TREK1 trafficking and function, and they highlight GPCR-based modulation of TREK1 as a potential therapeutic strategy for depressive disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lee S, Kim SC, Noh J, et al. Mosapride promotes internalization of a TREK1-HTR4 complex and exerts rapid antidepressant-like effects. Mol Psychiatry. 2026. PMID: 42542439. doi:10.1038/s41380-026-03786-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。